Sort
39,280 grants matching “leukemia”
Project 5
$643,512Scott W Lowe · Cold Spring Harbor Laboratory · P01 · FY2015 · CA
Immune reconstitution following autologous and allogeneic stem cell transplant
$643,479Frances Hakim · Division Of Basic Sciences - Nci · ZIC · FY2016 · CA
Preclinical development and clinical monitoring of adoptive immune therapy
$643,479Frances Hakim · Division Of Basic Sciences - Nci · ZIC · FY2016 · CA
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
$643,241Martin Carroll · University Of Pennsylvania · R01 · FY2019 · CA
Small-molecule MDM2 degraders
$643,104Shaomeng Wang · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
Proteolytic disregulation of the S326C mutant OGG1 DNA repair enzyme
$642,889Michele K Evans · National Institute On Aging · ZIA · FY2013 · AG
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
$642,804Renata Pasqualini · Rbhs -Cancer Institute Of New Jersey · R01 · FY2020 · CA
Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance
$642,786Neil P Shah · University Of California, San Francisco · R01 · FY2022 · CA
Project 1: Chromosome Inheritance
$642,693Bruce W Stillman · Cold Spring Harbor Laboratory · P01 · FY2019 · CA
Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
$642,579Stefanie Sarantopoulos · Duke University · R01 · FY2017 · HL
Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
$642,579Stefanie Sarantopoulos · Duke University · R01 · FY2019 · HL
Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
$642,579Stefanie Sarantopoulos · Duke University · R01 · FY2016 · HL
Brain Tumors - Immunological and Biological Studies
$642,571Darell D Bigner · Duke University · R37 · FY2007 · CA
Mechanisms and functions of N6-methyladenosine (m6A) in cancer
$642,546Samie R Jaffrey · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · CA
BREAKING B-CELL TOLERANCE TO PRODUCE ANTIBODIES THAT ERADICATE LEUKEMIAS AND LYMPHOMAS
$642,500Duke University · · FY2018 · Department of the Army
Development of Inhibitors of the Leukemia Fusion Protein CBFbeta-SMMHC
$642,418John Hackett Bushweller · University Of Virginia · R01 · FY2011 · CA
Role of TET2 mutations in malignant transformation and acute myeloid leukemia
$642,416Ross L Levine · Sloan-Kettering Inst Can Research · R01 · FY2018 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
$642,358Renata Pasqualini · Rbhs -Cancer Institute Of New Jersey · R01 · FY2021 · CA
AF9(MLLT3) Function in Leukemia and Normal Hematopoiesis
$642,234John Hackett Bushweller · University Of Virginia · R01 · FY2019 · CA
Processed Antigen Characterization by Mass Spectrometry
$641,956Donald F Hunt · University Of Virginia · R01 · FY2014 · AI
Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization
$641,950Suming Huang · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2022 · CA
Development of first-in-class ST2 inhibitors for treating graft-versus-host disease
$641,835Chao-Yie Yang · University Of Tennessee Health Sci Ctr · R01 · FY2019 · HL
Synergestic roles of SRF2 and RUNX1 in blood cell development and pathology
$641,790Dong-Er Zhang · University Of California, San Diego · R01 · FY2020 · DK
New retroviral restriction factor
$641,742Tatyana V. Golovkina · University Of Chicago · R01 · FY2019 · AI
Reversible Covalent BTK Degraders as the Next Generation Targeted Therapy to Treat B-cell Malignancies
$641,550Jin Wang · Baylor College Of Medicine · R01 · FY2021 · CA